Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 19, Issue 4, 2000, Pages 355-359

  Kelly, Janet ^a   Hurley, Dana ^a   Raghu, Ganesh ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; TACROLIMUS; VIRUS ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE;

ADULT; AGED; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEALTH CARE COSTS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RECURRENCE; REFERENCE VALUES; TREATMENT OUTCOME; WASHINGTON;

EID: 0034035775     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(00)00070-X     Document Type: Article

References (17)

1. Duncan A.J., Dummer J.S., Paradis I.L., et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 10:1991;638-646.
2. Dauber J.H., Paradis I.L., Dummer J.S. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 11:1990;279-290.
3. Dummer J.S., White L.T., Monto H., Griffith B.P., Hardesty R.L., Bahnson H.T. Morbidity of cytomegalovirus infection in recipients of heart or heart lung transplant who received cyclosporine. J Infect Dis. 152:1985;1182-1191.
4. Merigan T.C., Renlund D.G., Keay S., et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 326:1992;1182-1186.
5. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 118:1993;173-178.
6. Kelly J.L., Albert R.K., Wood D.E., Raghu G. Efficacy of 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation. 59:1995;1144-1147.
7. Niubo J., Perez J.L., Martinez-Lacasa J.L., et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis. 24:1996;19-24.
8. The T.H., van den Berg A.P., van Son I.J., et al. Monitoring for cytomegalovirus after organ transplantation a clinical perspective . Transpl Proc. 25:1993;5-9.
9. van den Berg A.P., Klompmaker I.J., Haagsma E.B., et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis. 164:1991;265-270.
10. Duncan S.R., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 146:1992;1419-1425.
11. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation. 66:1998;747-752.
12. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation a randomized double-blind study . Blood. 88:(10):1996;4063-4077.
13. Hutter J.A., Scott J., Weghitt T.G., Higenbottam T., Wallwork J. The importance of cytomegalovirus in heart-lung transplant recipients. Chest. 95:1989;627-631.
14. Wreghitt T.G., Hakim M., Gray J.J., et al. Cytomegalovirus infections in heart and heart and lung transplant recipients. J Clin Pathol. 41:1988;660-667.
15. Manez R., Kusne S., Green M., et al. Incidence and risk factors associated with development of cytomegalovirus disease after intestinal transplantation. Transplantation. 59:1995;1014-1024.
16. Koskinen P.K., Nieminen M.S., Mattila S.P., Hayry P.J., Lautenschlager I.T. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation. 55:1993;547-551.
17. Grossi P., Minoli L., Percivalle E., Irish W., Vigano M., Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation. 59:1995;847-851.